Ikena Oncology, Inc. (NASDAQ:IKNA, ", Ikena", , ", Company", )))), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an
Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer.